ALPX

IPO filed Mar 7, 2022 · latest amendment Oct 27, 2026

• S-1/Aamended IPO prospectusNegativeBankruptcy / going concernPre-revenueControlled company

  Filed Oct 26

  Develops PNAG-targeting vaccines and antibodies to prevent infections; seeks $30–$36M to fund proof-of-concept trials.

No filings match these filters. Show all 8-K events

Request longer coverage